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Edited by Varda RotterAbstract The role of caveolae and the caveolin proteins in can-
cer has been the subject of extensive research. BRCA1 partici-
pates in multiple biological pathways including DNA damage
repair, transcriptional control, cell growth, apoptosis, and oth-
ers. Little information, however, is available regarding the cellu-
lar mechanisms that control BRCA1 gene expression. The
present study examined the potential regulation of BRCA1 gene
expression and subcellular localization by Cav-1. Results of
Western blots, RT-PCR, and transfection experiments showed
that Cav-1 enhances BRCA1 protein and mRNA levels via a
mechanism that involves transactivation of the BRCA1 promoter
and which is p53-dependent. In addition, immunostaining exper-
iments demonstrate that Cav-1 induced the cytoplasmic seques-
tration of BRCA1.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Caveolae are non-clathrin-coated ﬂask-shaped invaginations
of the plasma membrane which were ﬁrst identiﬁed as endocytic
structures involved in the transport of macromolecules across
endothelial cells [1]. One of the main structural components
of caveolae are the caveolins, the products of a mammalian
gene family comprised of Cav-1, -2 and -3. Cav-1 and -2 are
coexpressed in many cell types, and they form both homooligo-
meric and heterooligomeric complexes. Cav-3, on the other
hand, is a muscle-speciﬁc protein [2]. Cav-1, a 22-kDa protein,
constitutes an integral part of the striated coat of caveolae [3,4].
Upon Cav-1 integration into the microenvironment of a lipid
raft, these microdomains invaginate and form caveolae [5].
Furthermore, by virtue of its capacity to act as a scaﬀolding
protein able to organize and concentrate speciﬁc lipids and li-
pid-modiﬁed signaling molecules within caveolar membranes,
Cav-1 participates in vesicular traﬃcking events and also in a
number of signal transduction processes [1,2].
The role of caveolae and the caveolin proteins in cancer has
been the subject of extensive research and continuing debate.
Disruption of caveolar integrity appears to be a common theme*Corresponding author. Fax: +972 3 6406087.
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doi:10.1016/j.febslet.2006.08.071in oncogenic transformation. Furthermore, malignant transfor-
mation is usually associated with a reduction in the cellular level
of caveolin [5–7]. In addition, Cav-1 has been shown to inhibit
the activity of several caveolae-associated signaling molecules,
including Src tyrosine kinase family members, Ha-Ras, endo-
thelial nitric oxide synthase, heterotrimeric G proteins, etc.
Given that many of these proteins display oncogenic types of
activities, it has been suggested that Cav-1 possesses a transfor-
mation-suppressing activity [8]. Consistent with this notion,
antisense-mediated downregulation of Cav-1 in NIH-3T3 ﬁbro-
blasts led to anchorage-independent growth and hyperactiva-
tion of the MAPK pathway [9]. In addition, forced expression
of Cav-1 in the human breast cancer cell line MCF7 suppressed
proliferation, cell viability, and anchorage-independent growth
[10–12]. Furthermore, a dominant-negative mutant Cav-1 mol-
ecule (P132L) was reported to be present in about 16% of the
cases out of a collection of 92 primary human breast cancers
[13]. Finally, genetic knockout of Cav-1 results in mammary
gland ductal epithelial cell hyperplasia [14] and greatly acceler-
ates tumorigenesis in MMTV-PyMT mice prone to develop-
ment of mammary gland tumors [15,16]. On the other hand,
evidence in support of an oncogenic role for Cav-1 was provided
by studies showing that Cav-1 promotes cell survival in meta-
static prostate cancer cells [17,18] and inhibits anoikis in
MCF7 breast cancer cells [12]. In addition, Cav-1 gene knock-
out was recently shown to promote apoptosis in the TRAMP
mouse prostate cancer model [19]. Indeed, Cav-1 expression is
upregulated in numerous cancer cell lines and tumor specimens,
and Cav-1 expression often correlates with cancer cell grade and
tumor progression stage (reviewed in Liscovitch et al. [20]).
The familial breast cancer susceptibility gene, BRCA1,
encodes a 220-kDa phosphorylated protein with putative
tumor suppressor activity. The human BRCA1 gene has been
mapped to chromosome 17q21 [21]. Mutated forms of BRCA1
were correlated with the appearance of familial breast and/or
ovarian cancer at very young ages [21,22], although BRCA1
has been also implicated in cases of sporadic breast cancer
[23–27]. BRCA1 participates in multiple biological pathways,
including DNA damage repair, transcriptional control, cell
growth, and apoptosis [27]. BRCA1 is normally a nuclear pro-
tein which is targeted to the nucleus via two nuclear localiza-
tion signal (NLS) sequences [28–30]. Many breast and
ovarian cancer cell lines and primary tumors, on the other
hand, exhibit a predominantly cytoplasmic pattern of distribu-
tion [31,32]. Little information, however, is available regarding
the cellular mechanisms that are responsible for BRCA1 gene
expression and cellular localization.blished by Elsevier B.V. All rights reserved.
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breast cancer development, we examined in the present study
the potential regulation of BRCA1 gene expression by Cav-
1. The results obtained showed that Cav-1 upregulates BRCA1
protein and mRNA levels by enhancing transcription of the
BRCA1 promoter in a p53-dependent fashion. In addition,
Cav-1 expression had a signiﬁcant impact on BRCA1 subcellu-
lar localization, with Cav-1-expressing cells displaying a pri-
marily cytoplasmic pattern of distribution compared to its
predominantly nuclear localization in Cav-1-null cells. Interac-
tions between Cav-1 and BRCA1 may have important conse-
quences in terms of breast cancer biology.Fig. 1. Regulation of BRCA1 gene expression by Cav-1. (A) RT-PCR
analysis of BRCA1 mRNA levels in MCF7 and MCF7/Cav-1 cells.
Total RNA was isolated from the MCF7 and MCF7/Cav-1 cell lines
and semi-quantitative RT-PCR analysis of BRCA1 and GAPDH
mRNA levels was performed as described in Section 2. The positions
of BRCA1 mRNA and GAPDH mRNA are indicated by the arrows.
(B) BRCA1 mRNA levels were quantitated by densitometric scanning
and expressed as BRCA1 mRNA values normalized to the corre-
sponding GAPDH mRNA band. Results are means ± S.E.M. of three
independent experiments. *, P < 0.05 versus MCF7 cells. (C) Western
blot analysis of BRCA1 levels. MCF7 and MCF7/Cav-1 cells were
lysed as indicated in Section 2. Equal amounts of protein (80 lg) were
resolved by 8% SDS–PAGE and transferred onto nitrocellulose
membranes. Membranes were blotted with a polyclonal BRCA1
antibody, followed by incubation with a horseradish peroxidase
conjugated secondary antibody. Membranes were re-blotted with
anti-tubulin. The positions of the 220-kDa BRCA1 and 50-kDa
tubulin bands are indicated by arrows. Shown is a typical experiment
repeated 4–6 times with similar results.2. Materials and methods
2.1. Cell cultures
Human breast adenocarcinoma MCF7 cells were kindly provided by
Dr. Merril E. Goldsmith (National Cancer Institute, Bethesda, MD,
USA). The generation of the Cav-1-transfected MCF7/Cav-1 cell line
was described previously [12]. MCF7/pSUPER-p53 cells, expressing
a siRNA against p53, and control MCF7/pSUPER cells were kindly
provided by Dr. Reuven Agami (Netherlands Cancer Institute,
Amsterdam, The Netherlands). All of the cell lines were maintained
in RPMI-1640 medium supplemented with 10% heat-inactivated fetal
bovine serum (FBS), 2 mM glutamine, and 50 lg/ml gentamicin sul-
fate. MCF7/Cav-1 cells were routinely supplemented with 400 lg/ml
G418 (InVitrogen, Carlsbad, CA, USA), and transferred to drug-free
medium before the experiments. MCF7/pSUPER and MCF7/pSU-
PER-p53 were selected with 1 lg/ml puromycin (Sigma–Aldrich, Saint
Louis, MO, USA).
2.2. Luciferase reporter plasmids, transfections and promoter activity
measurements
For transient transfection experiments, the pGL3-I plasmid, con-
taining the full-length BRCA1 promoter region (nucleotides 1–2696)
subcloned upstream of a luciferase reporter gene in the pGL3-basic
vector, was employed [33]. A full-length wild-type Cav-1-expression
vector was generated by subcloning a myc-tagged murine Cav-1 cDNA
into pcDNA3. To normalize for transfection eﬃciency, cells were
cotransfected with a b-galactosidase expression vector (pCMVb; Clon-
tech, Palo Alto, CA, USA). Each 60-mm dish received 1 lg of reporter
plasmid, 0.2 lg of pCMVb, and variable amounts of Cav-1 expression
vector using the jetPEI transfection reagent (Poly-Plus, Illkirch,
France). The total amount of DNA transfected was kept constant with
empty pcDNA3 vector. Luciferase and b-galactosidase activities were
measured after 48 h, as previously described [34]. Promoter activities
were expressed as luciferase values normalized for b-galactosidase
activity.
2.3. Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was prepared using the AquaPure RNA Isolation kit
(Bio Rad, Hercules, CA, USA). BRCA1 mRNA levels were measured
by semiquantitative RT-PCR. Total RNA (2600 ng) was used to syn-
thesize a single strand cDNA using Superscript III Reverse Trans-
criptase (InVitrogen). BRCA1 mRNA levels were measured using
the following primers: sense, 5 0-GGTGGTACATGCACAGTTGC-
3 0; antisense, 5 0-TGACTCTGGGGCTCTGTCTT-30. The size of the
ampliﬁed BRCA1 mRNA fragment was 241-bp. For control purposes,
levels of GAPDH mRNA were measured in the same tubes using the
following primers: sense, 5 0-ACCACAGTCCATGCCATCAC-30 and
antisense, 5 0-TCCACCACCCTGTTGCTGTA-30 [35]. The size of
the ampliﬁed GAPDH mRNA fragment was 452-bp.
2.4. Western blot analysis
Cells were harvested with ice-cold phosphate-buﬀered saline (PBS)
and lysed in a lysis buﬀer containing 50 mM Tris–HCl, pH 7.4–7.6
and 2% SDS in the presence of a protease inhibitor cocktail. Protein
content was determined using the BCA Protein Assay method (Pierce,
Rockford, IL, USA) using bovine serum albumin as a standard. Sam-
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SDS–PAGE and transferred to a nitrocellulose membrane. After
blocking with 3% skim milk, membranes were blotted with a poly-
clonal anti-BRCA1 antibody (C-20, Santa Cruz Biotechnology, Santa
Cruz, CA, USA). To measure p53 levels, blots were incubated with a
mixture of two p53 antibodies (DO-1 and Pab1801, Santa Cruz Bio-
technology). Blots were re-probed with anti-tubulin. The secondary
antibodies were anti-mouse or anti-rabbit IgG conjugated to horserad-
ish peroxidase (Jackson Immunoresearch Laboratories, West Grove,
PA, USA). Proteins were detected using the SuperSignal West Pico
Chemiluminescent Substrate (Pierce).
2.5. Immunoﬂuorescence microscopy
Cells were seeded on glass coverslips the day before immunostaining.
Following washing with cold sterile PBS, ﬁxation was performed in 2%
formaldehyde diluted in sterile PBS for 20 min. Cells were then incu-
bated for 1 hwith anti-BRCA1C-20 (dilution 1:300) orAb-1 (Oncogene
Science, Cambridge, MA, USA). Cells were then permeabilized and
blockedwith 0.1%Saponine (Sigma–Aldrich) in 1.5%FBS in PBS.After
washingwith PBS, slides were incubated for 1 hwith Cy TM3 conjugated
Aﬃnitipure goat anti-rabbit IgG (Jackson Immuno Research) or with
AlexaFluor 488 goat anti-mouse IgG (Molecular Probes, Eugene, OR,
USA). Nuclei were stained brieﬂy with 5 lg/ml DAPI (4,6-diamidino-
2-phenylindole). The subcellular localization of BRCA1 was obtained
by scoring cells with a Leica TCF SP2 confocal microscope.3. Results
3.1. Regulation of BRCA1 mRNA and protein levels by Cav-1
BRCA1 functions as a tumor suppressor capable of arrest-
ing growth of mammary-derived cells [36]. In addition, recent
experiments have shown that stable expression of Cav-1 inFig. 2. Regulation of BRCA1 promoter activity by Cav-1. MCF7 and
MCF7/Cav-1 cells were cotransfected with the full-length BRCA1
promoter luciferase reporter construct (pGL3-I), along with a pCMVb
control plasmid, as described in Section 2. Promoter activities are
expressed as luciferase values normalized for b-galactosidase levels. A
value of 100% was given to the promoter activity in MCF7 cells. Bars
are means ± S.E.M. of a typical experiment repeated three times. *,
P < 0.05 versus MCF7 cells.
Fig. 3. Eﬀect of p53 on the regulation of BRCA1 gene expression by
Cav-1. Untransfected MCF7/pSUPER and MCF7/pSUPER-p53 were
harvested, lysates were electrophoresed through 8% SDS–PAGE, and
endogenous p53 (A) and BRCA1 (B) levels were measured by Western
blot. The positions of the p53 and BRCA1 bands are denoted by the
arrows. Membranes were re-probed with a tubulin antibody. (C)
MCF7/pSUPER and MCF7/pSUPER-p53 cells were transfected with
0.5 lg of a Cav-1 expression vector (or empty pcDNA3) and, after
48 h, endogenous BRCA1 and tubulin levels were measured by
Western blots. (D) MCF7/pSUPER and MCF7/pSUPER-p53 cells
were transiently cotransfected with 1 lg of the full-length BRCA1
promoter-luciferase reporter plasmid (pGL3-I) and 0.5 lg of a Cav-1
expression vector (solid bar), or empty pcDNA3 expression vector
(open bar), along with 0.2 lg of pCMVb, using the jetPEI reagent.
After 48 h, luciferase and b-galactosidase levels were measured.
Promoter activities are expressed as luciferase normalized for b-
galactosidase levels. A value of 100% was given to the basal BRCA1
promoter activity, in the absence of Cav-1. Bar graphs represent
smean ± S.E.M. of three independent experiments. *, P < 0.05 versus
pcDNA3-transfected cells.
C. Glait et al. / FEBS Letters 580 (2006) 5268–5274 5271MCF7 mammary adenocarcinoma cells attenuates prolifera-
tion and blocks anchorage-independent growth [12]. To inves-
tigate whether Cav-1 regulates BRCA1 gene expression, total
RNA was obtained from untreated MCF7 and MCF7/Cav-1
cells, and BRCA1 and GAPDH mRNA levels were measured
by semi-quantitative RT-PCR. As shown in Fig. 1A and B,
endogenous BRCA1 mRNA levels were 2.7 ± 0.8-fold higher
in MCF7/Cav-1 than in MCF7 cells. No changes were detected
in GAPDH mRNA levels.
To assess whether the Cav-1-induced increase in BRCA1
mRNA levels was associated with a corresponding elevation
in BRCA1 protein levels, lysates were prepared from MCF7/
Cav-1 and control MCF7 cells, electrophoresed through 8%
SDS–PAGE gels and immunoblotted with a BRCA1 antibody
(C-20). Results of multiple Western blot analyses showed that
BRCA1 levels were approximately 40% higher in MCF7/Cav-1
than in native MCF7 cells (Fig. 1C).3.2. Eﬀect of Cav-1 on BRCA1 promoter activity
To determine whether the eﬀect of Cav-1 on BRCA1 mRNA
levels was mediated at the level of transcription, a luciferase
reporter construct containing the entire 2.7-kb BRCA1
promoter sequence (pGL3-I) was transiently transfected into
both MCF7 and MCF7/Cav-1 cell lines, along with the
pCMVb control plasmid. After 48 h, cells were harvested
and luciferase and b-galactosidase values were measured.
Results of transfection experiments showed that BRCA1Fig. 4. Immunoﬂuorescence staining of BRCA1 with anti-BRCA1 C-20. MC
and maintained as described in Section 2. Following ﬁxation in 2% forma
antibody (C-20), diluted in 0.1% Saponine with 1.5% FCS in PBS. Cells were
in PBS and incubated with Cy TM3 conjugated Aﬃnitipure, goat anti-rabbit
[blue; (B,E)]. The composite images of two-color staining are presented in Apromoter activity was 3-fold higher (297.4 ± 17.0%) in
MCF7/Cav-1 cells compared with control MCF7 cells, sug-
gesting that the mechanism responsible for the augmented
BRCA1 mRNA levels in Cav-1-expressing cells involves trans-
activation of the BRCA1 promoter (Fig. 2).3.3. Involvement of p53 in transcriptional regulation of the
BRCA1 promoter by Cav-1
Since previous studies have established that BRCA1 works
in conjunction with tumor suppressor p53 [37], we investigated
the potential participation of p53 in regulation of BRCA1 gene
expression by Cav-1. For this purpose we employed an MCF7-
derived cell line in which p53 expression was suppressed by sta-
ble transfection of a p53-RNAi vector (MCF7/pSUPER-p53)
[38] and control, empty vector-transfected, cells (MCF7/pSU-
PER) expressing a wild-type p53 (Fig. 3A). Western blot anal-
ysis with a BRCA1 antibody revealed no distinct changes in
basal BRCA1 expression levels between p53-expressing and
p53-null cells (Fig. 3B). MCF7/pSUPER and MCF7/pSU-
PER-p53 cells were transiently transfected with a Cav-1
expression vector, and after 48 h endogenous BRCA1 levels
were measured by Western blots. Results obtained showed that
Cav-1 expression induced a 33% increase in BRCA1 levels in
p53-containing cells, whereas it reduced BRCA1 levels by
more than 90% in p53-null cells (Fig. 3C). To assess whether
the eﬀect of p53 was mediated at the level of transcription of
the BRCA1 gene, MCF7/pSUPER and MCF7/pSUPER-p53F7 (A–C) and MCF7/Cav-1 (D–F) cells were grown on glass coverslips
ldehyde, immunostaining was performed using a polyclonal BRCA1
permeabilized in the presence of 0.1% Saponine with 1.5% FCS diluted
IgG [red; (C,F)]. Nuclear localization was assessed by DAPI staining
and D. The scale bars denote 20 lm.
Fig. 5. Immunoﬂuorescence staining of BRCA1 with anti-BRCA1 Ab-1.MCF7 (A–C) and MCF7/Cav-1(D–F) cells were grown on glass coverslips
and maintained as described in Section 2. Cells were processed as described in the legend to Fig. 4 and incubated with AlexaFlour 488, goat anti-
mouse IgG [green; (C,F)]. Nuclear localization was assessed by DAPI staining [blue; (B,E)]. The composite images of two-color staining are presented
in A and D.
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vector (or empty pcDNA3), along with the full-length BRCA1
promoter-luciferase reporter vector (pGL3-I), or empty pGL3-
basic promoter plasmid as a negative control. As shown in
Fig. 3D, Cav-1 induced a 174.73 ± 0.77% increase in BRCA1
promoter activity in MCF7 pSUPER cells, whereas it had a
small inhibitory eﬀect in p53-depleted cells (86.87 ± 3.33% de-
crease). These results suggest that the stimulatory eﬀect of
Cav-1 on BRCA1 promoter activity is p53-dependent. Cav-1
had no eﬀect on the empty pGL3-basic promoter (data not
shown).3.4. Eﬀect of Cav-1 on BRCA1 subcellular localization
Immunoﬂuorescent staining of BRCA1 was performed to
investigate whether Cav-1 can modulate BRCA1 subcellular
localization. To this end, MCF7 and MCF7/Cav-1 cells were
seeded on glass cover slips and BRCA1 distribution was ana-
lyzed using a polyclonal anti-BRCA1 antibody (C-20) raised
against the C-terminal portion of human BRCA1 (Fig. 4)
and a monoclonal anti-BRCA1 antibody (Ab-1) raised against
the N-terminus of BRCA1 (Fig. 5). In MCF7 cells, BRCA1
exhibited a typical immunoreactivity pattern which consisted
of a punctuated nuclear staining, with cytoplasmic staining
(A–C) [32]. In contrast, in MCF7/Cav-1 cells BRCA1 was pre-
dominantly localized in the cytoplasm (D–F). The DAPI coun-
ter staining conﬁrmed the identity of nuclei in both cell lines
(B,E). Similar results were obtained with a polyclonal anti-
BRCA1 antibody (D-20) raised against the N-terminal portion
of human BRCA1 (data not shown).4. Discussion
Tumor suppressor BRCA1 has been shown to be involved in
the regulation of a number of biological processes in various
cellular and animal models [27]. Cav-1, a major component
of the caveolar membrane, modulates the activity of several
signaling molecules, including G proteins, members of the
MAPK cascade, and others [39,40]. The present study was de-
signed to examine the potential regulation of BRCA1 gene
expression by Cav-1. The rationale for our emphasis on a func-
tional interaction between these two proteins lies in the fact
that Cav-1 and BRCA1 were identiﬁed as tumor suppressors
with important roles in the etiology of breast cancer. Little
information, however, is available regarding the cellular fac-
tors involved in regulation of BRCA1 gene expression. This
study identiﬁes the BRCA1 gene as a novel downstream target
for Cav-1 action in breast cancer cells.
Semiquantitative RT-PCR analysis of BRCA1 mRNA levels
in Cav-1-overexpressing MCF7 cells revealed a 2.7-fold in-
crease in transcript abundance compared to native MCF7
cells. This increase was associated with an elevation in endo-
genous BRCA1 protein levels, although the extent of BRCA1
increase at the protein level was lower than that seen at the
mRNA level. Results of transient transfection experiments
using a full-length BRCA1 promoter reporter construct are
consistent with the notion that the enhanced BRCA1 mRNA
values in MCF7/Cav-1 cells are the result of augmented
BRCA1 gene transcription. The Cav-1-induced transcription
factors that are directly responsible for BRCA1 gene transac-
tivation, however, remain to be identiﬁed.
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in the nucleus, although it can shuttle between the nucleus and
cytoplasm [41]. Our results demonstrate a clear diﬀerence in
BRCA1 subcellular localization between Cav-1-expressing
and Cav-1-null cells. Speciﬁcally, MCF7 cells exhibited a typ-
ical nuclear dotted pattern of expression whereas MCF7/Cav-1
cells displayed mainly a cytoplasmic distribution. Mislocaliza-
tion of BRCA1 in the cytoplasm of Cav-1-expressing cells may
result from aberrations in BRCA1 nuclear transport. BRCA1
includes two NLS in the central portion of the molecule
[29,30], although BRCA1 can be also targeted to the nucleus
in an NLS-independent manner [42]. In addition, the BRCA1
RING domain, located in the N-terminal portion of the pro-
tein, participates in nuclear targeting via interaction with
BARD1 [43,44]. BARD1 binding was shown to mask the
BRCA1 nuclear export signal, thus leading to nuclear accumu-
lation of BRCA1 [45]. The BRCA1/BARD1 complex is also
known to possess auto-ubiquitination activity [46–48]. It has
been suggested that upon dissociation from BARD1, ubiquiti-
nated BRCA1 is exported to the cytoplasm and degraded by
the proteasome complex [42]. We may speculate that the rela-
tively small increase in BRCA1 protein levels in MCF7/Cav-1
cells, in comparison to the more pronounced increase in
mRNA levels, results from the Cav-1-induced cytoplasmic
sequestration of BRCA1. The net consequence of this event
is an enhanced cytoplasmic degradation of BRCA1.
Various lines of evidence suggest that BRCA1 and p53 act
synergistically in the control of cellular proliferation. Tumor
suppressor p53 has a central role in the control of the apopto-
tic process and in the regulation of the DNA damage response.
Speciﬁcally: (i) BRCA1 and p53 were shown to physically
interact [37]; (ii) BRCA1 stimulated promoter constructs con-
taining speciﬁc p53-response elements [49]; (iii) p53 regulated
BRCA1 expression in response to DNA damage at the tran-
scriptional level [33]; and (iv) BRCA1 is a potent activator of
p53-dependent transcription [37]. Consistent with these ﬁnd-
ings, we show here that upregulation of BRCA1 promoter
activity by Cav-1 requires an intact p53 signaling pathway.
In summary, we have demonstrated that a novel mechanism
of action of Cav-1 in breast cancer cells involves the p53-
dependent transcriptional activation of the BRCA1 gene, with
ensuing increase in BRCA1 mRNA levels. In addition, Cav-1
expression leads to BRCA1 exclusion from the nucleus. Ele-
vated BRCA1 levels may account for the Cav-1-induced reduc-
tion in proliferation rate and anchorage-independent growth in
MCF7 cells. Aberrant regulation and/or expression of Cav-1
may lead to pathologic dysregulation of BRCA1 levels and
localization, with potentially important consequences in breast
cancer development.
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